Show simple item record

dc.contributor.authorEcheverria, Patricia
dc.contributor.authorBonjoch, Anna
dc.contributor.authorPuig Batalla, Jorge
dc.contributor.authorMolto, Jose
dc.contributor.authorParedes, Roger
dc.contributor.authorSirera, Guillem
dc.contributor.authorOrnelas, Arelly
dc.contributor.authorPérez Álvarez, Nuria
dc.contributor.authorClotet, Bonaventura
dc.contributor.authorNegredo, Eugènia
dc.contributor.otherUniversitat Politècnica de Catalunya. Departament d'Organització d'Empreses
dc.contributor.otherUniversitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa
dc.identifier.citationEcheverria, P. [et al.]. Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study. "PLoS One", 04 Febrer 2014, vol. 9, núm. 2.
dc.description.abstractBackground: Etravirine (ETR) was approved for patients with virological failure and antiretroviral resistance mutations. It has also shown antiviral efficacy in antiretroviral-naive patients. However, data on the switching from protease inhibitors (PI) to ETR are lacking.; Methods: HIV-1-infected patients with suppressed viral load (VL) during a PI-containing regimen (>12 months) and no previous virological failure were randomized to switch from the PI to ETR (400 mg/day, dissolved in water) (ETR group, n = 22) or to continue with the same regimen (control group, n = 21). Percentage of patients with VL <= 50 copies/mL were assessed at week 48, as well as changes in CD4 T-cell counts and metabolic profile.; Results: We included 43 patients [72.9% male, 46.3 (42.2; 50.6) years]. Two patients receiving ETR (grade-1 diarrhea and voluntary discontinuation) and another in the control group (simplification) discontinued therapy early. No patients presented virological failure (two consecutive VL>50 copies/mL); treatment was successful in 95.2% of the control group and 90.9% of the ETR group (intention-to-treat analysis, missing = failure) (p = 0.58). CD4+ T-cell counts did not significantly vary [+49 cells/mu L in the ETR group (p = 0.25) and -4 cells/mu L in the control group (p = 0.71)]. The ETR group showed significant reductions in cholesterol (p<0.001), triglycerides (p=<0.001), and glycemia (p = 0.03) and higher satisfaction (0-10 scale) (p = 0.04). Trough plasma concentrations of ETR were similar to observed in studies using ETR twice daily.; Conclusion: Switch from a PI-based regimen to a once-daily combination based on ETR maintained undetectable VL during 48 weeks in virologically suppressed HIV-infected patients while lipid profile and patient satisfaction improved significantly.
dc.rightsAttribution 3.0 Spain
dc.subjectÀrees temàtiques de la UPC::Ciències de la salut
dc.subject.lcshVirus-induced immunosuppression
dc.subject.lcshHIV (Viruses)--Research
dc.subject.otherReverse-transcriptase inhibitor
dc.subject.otherPlacebo-controlled trial
dc.subject.otherExperienced HIV-1-infected patients
dc.subject.otherTreatment-naive patients
dc.subject.otherTMC125 etravirine
dc.subject.otherAntiretroviral treatment
dc.subject.otherLipid profiles
dc.titleRandomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study
dc.subject.lemacVIH (Virus) -- Tractament
dc.contributor.groupUniversitat Politècnica de Catalunya. GREMA - Grup de Recerca en Estadística Matemàtica i les seves Aplicacions
dc.description.peerreviewedPeer Reviewed
dc.rights.accessOpen Access
dc.description.versionPostprint (published version)
upcommons.citation.authorEcheverria, P.; Bonjoch, A.; Puig, J.; Molto, J.; Paredes, R.; Sirera, G.; Ornelas, A.; Perez, N.; Clotet, B.; Negredo, E.
upcommons.citation.publicationNamePLoS One

Files in this item


This item appears in the following Collection(s)

Show simple item record

Except where otherwise noted, content on this work is licensed under a Creative Commons license: Attribution 3.0 Spain